Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research
QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies
In conclusion, we found a low risk of QTcF interval prolongation in children with RR-TB who received at least one QT-prolonging drug. Greater increases in maximum QTcF and ΔQTcF were observed when MFX and CFZ were used together. Future studies characterizing exposure-QTcF responses in children will be helpful to ensure safety with higher doses if required for effective treatment of RR-TB.PMID:37358463 | DOI:10.1128/aac.01448-22 (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - June 26, 2023 Category: Microbiology Authors: Ali Mohamed Ali Kendra K Radtke Anneke C Hesseling Jana Winckler H Simon Schaaf Heather R Draper Bel én P Solans Louvina van der Laan Jennifer Hughes Barend Fourie James Nielsen Anthony J Garcia-Prats Rada M Savic Source Type: research
